Novo Nordisk says the US FDA has approved a once daily pill version of Wegovy, described as the first approved pill of its kind The company said trials showed average weight loss of 16.6%, with about a third of roughly 1,300 participants losing 20% or more Novo Nordisk expects a US launch in early January 2026, with investors pushing shares up sharply after the announcement amid strong competition in the weight loss market US regulators have approved an oral version of Wegovy for chronic weight management, giving Novo Nordisk the first daily pill in this drug class cleared for obesity treatment, according to the company and US media reports
These strips improve the immune system's ability to fight bacterial, viral, and fungal infections when consumed regularly
All peptides in this article are contraindicated
In these studies, the people who participated accomplished 15-20% weight loss on average of their overall body weight
PlexusDx offers the Precision Peptide Genetic Testa peptide-pathway genetic analysis that identifies your unique GLP-1 receptor sensitivity, GIPR pathway function, and metabolic gene variants
Epub 2019 Jun 7
